BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan FacilityPRNewsWire • 01/29/26
BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan FacilityPRNewsWire • 01/26/26
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-TermZacks Investment Research • 01/16/26
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth StockZacks Investment Research • 01/13/26
BioMarin Pharmaceutical Inc. (BMRN) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CAPRNewsWire • 01/08/26
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLDBusiness Wire • 12/26/25
BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8BZacks Investment Research • 12/22/25
BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping.Barrons • 12/19/25
BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion DealInvestors Business Daily • 12/19/25
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial OutlookPRNewsWire • 12/19/25